Benjamin Alman, MD, is an orthopaedic surgeon-scientist whose research focuses on understanding how developmental and regenerative signaling pathways contribute to musculoskeletal disease, tissue repair, fibrosis, and tumorigenesis. The long-term goal of his research program is to translate fundamental biologic discoveries into new therapies for musculoskeletal disorders. His laboratory makes extensive use of genetically engineered mouse models, single-cell genomics, and translational studies to identify mechanisms underlying disease and repair. This work has led to the identification of novel therapeutic targets for musculoskeletal tumors and new approaches to improve cartilage, bone, and soft tissue regeneration.
Dr. Alman's research has also advanced understanding of cellular heterogeneity in musculoskeletal tumors and normal skeletal tissues. His laboratory identified tumor-initiating cell populations in sarcomas and has defined distinct mesenchymal cell populations that regulate skeletal development, fibrosis, and fracture repair.
Dr. Alman has been involved in desmoid tumor research since the beginning of his scientific career, with a sustained focus spanning more than three decades. His work has helped define the molecular pathogenesis of desmoid tumors, particularly the role of the Wnt/β-catenin signaling pathway, and has contributed to the development of targeted therapeutic strategies. He plays a leadership role in the field by organizing and facilitating the annual DTRF International Desmoid Tumor Research Workshop, fostering collaborations among basic scientists, translational investigators, clinicians, and patient advocates.
Dr. Alman is the James R. Urbaniak Professor and Chair of the Department of Orthopaedic Surgery at Duke University School of Medicine. He leads one of the nation's largest academic orthopaedic departments, with internationally recognized programs in clinical care, education, and musculoskeletal research. Despite his administrative responsibilities, he maintains a highly active, NIH-funded translational research program with protected time dedicated to advancing discoveries that improve outcomes for patients with musculoskeletal disease.
